MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
BPDCN is a rare and highly aggressive hematologic malignancy, often with cutaneous manifestations, with historically poor outcomes.
BPDCN typically presents in the bone marrow and/or skin and may also involve lymph nodes and viscera. The diagnosis of BPDCN is based on the immunophenotypic diagnostic triad of CD123, CD4, and CD56, as well as other markers. The World Health Organization (WHO) termed this disease “BPDCN” in 2008; previous names included blastic NK cell lymphoma and agranular CD4+/CD56+ hematodermic neoplasm.
For more information, please visit the BPDCN disease awareness website at www.bpdcn.eu.
Stemline Therapeutics, acquired by Menarini Group in June 2020, brought the very first treatment approved for patients with BPDCN and the first CD123-directed therapy to the market in the U.S after FDA approval. The treatment has received a recent approval also in EU (January 2021).
